RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
US9453220B2 · kind B2 · utility
1Cited by
1References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 23, 2014 |
| Grant date | Sep 27, 2016 |
| Priority date | — |
| Expiry date | Mar 2, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.